BIF-1 expression in human cancers: roles in apoptosis, autophagy, and therapeutic potential

Rahimi, Hasti, Dehghani, Fatemeh, Rabani, Mahta, Shafiee, Fatemeh
European Biophysics Journal · Springer Nature · 2026-12-01 · DOI: 10.1007/s00249-026-01867-y

Abstract

Bax-interacting factor-1 (BIF-1), also known as endophilin B1 (SH3GLB1), is a membrane-associated protein involved in apoptosis, autophagy, and membrane dynamics. There is growing evidence of a context-dependent role in tumor biology, mainly associated with tumor-suppressive functions in several cancers. In this narrative review, we summarize current evidence regarding BIF-1 expression patterns and its functional relevance in cancer-related pathways. Downregulation of BIF-1 has been consistently reported in melanoma, breast cancer, prostate cancer, gastric carcinoma, colorectal cancer, urinary bladder cancer and gallbladder cancer, where reduced expression is associated with impaired apoptosis, altered autophagy and tumor progression, supporting its potential value as a tumor suppressor-associated biomarker. On the other hand, hepatocellular carcinoma shows a context-dependent expression pattern and inconsistent associations with clinical outcomes. Its clinical utility in these tumors is limited because diagnostic and prognostic significance has not been consistently demonstrated. Therapeutic studies suggest that modulation of BIF-1-related pathways could influence autophagy, apoptosis and cellular metabolism, implying indirect participation in cancer treatment strategies. In general, BIF-1 seems to be a potential biomarker linked to tumor suppression in various epithelial cancers, especially in melanoma, breast, and prostate cancers. However, it’s clinical utility remains limited or appears variable in pancreatic ductal adenocarcinoma and Merkel cell carcinoma. These findings highlight the context-dependent role of BIF-1 in tumor biology. Graphical abstract The graphical abstract provides a schematic overview of the diverse biological functions of BIF-1 (Endophilin B1/SH3GLB1) in apoptosis, autophagy, mitochondrial dynamics, and tumor biology. It illustrates the role of BIF-1 in mitochondrial fission and Bax-mediated apoptotic signaling, as well as its interaction with UVRAG and Beclin-1, which promotes activation of the class III PI3K (Vps34) complex and subsequent autophagosome formation through the recruitment of LC3 and Atg5. The figure also highlights the involvement of BIF-1 in COPI vesicle biogenesis and endocytic trafficking pathways. The lower panel summarizes the association between aberrant BIF-1 expression and the development or progression of multiple malignancies, including breast, prostate, colorectal, gastric, hepatocellular, urinary bladder, gallbladder, and melanoma. In addition, current and emerging therapeutic approaches targeting BIF-1 are depicted, including conventional chemotherapeutic agents, autophagy-modulating compounds, nanomedicine-based drug delivery systems, and the novel BIF-1–iRGD fusion protein developed for selective targeting of integrin-overexpressing tumor cells. Overall, the graphical abstract presents an integrated view of the molecular functions of BIF-1 and its potential as a therapeutic target in cancer.

Read at publisher →

Similar articles